Science Explorer Back to mapMap
Discussion
Company · Lexington · United States

Epix Pharmaceuticals (United States)

epixpharma.comROR OpenAlex
World rank, all time
#31,442
of 34,923
Rank in United States
#6,649
of 7,310
Research works
158
▲ 102% vs 2018-21
Citations
7.1k
44.7 per fractional work
Top-10% rate
6.9%
all institutions 10.0%
vs its own fields
1.11×
1.00× is exactly expected
Open access
27%
world 40%
International
18%
world 18%
Epix Pharmaceuticals (United States)

Which fields of science does Epix Pharmaceuticals (United States) work in?

In 2022-now, 59% of research at Epix Pharmaceuticals (United States) is in Health Sciences, 28% in Life Sciences. Its largest fields are Medicine (57%), Biochemistry, Genetics and Molecular Biology (13%), Immunology and Microbiology (8%). It does 2.1× the world's share of Health Sciences.

Health Sciences: 21 fractional works · 58.8% of its workMedicine: 21 fractional works · 57.4% of its workRadiology, Nuclear Medicine and Imaging: 5 fractional works · 12.6% of its workPulmonary and Respiratory Medicine: 3 fractional works · 9.0% of its workOncology: 3 fractional works · 8.8% of its workPublic Health, Environmental and Occupational Health: 2 fractional works · 5.3% of its workSurgery: 1 fractional works · 4.0% of its workGastroenterology: 1 fractional works · 3.0% of its workOphthalmology: 1 fractional works · 1.9% of its workPharmacology: 1 fractional works · 1.7% of its workEpidemiology: 1 fractional works · 1.6% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 1.2% of its workPediatrics, Perinatology and Child Health: 0 fractional works · 1.1% of its workGenetics: 0 fractional works · 0.9% of its workRheumatology: 0 fractional works · 0.9% of its workAnesthesiology and Pain Medicine: 0 fractional works · 0.9% of its workHepatology: 0 fractional works · 0.7% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 0.7% of its workPsychiatry and Mental health: 0 fractional works · 0.6% of its workNeurology: 0 fractional works · 0.6% of its workPathology and Forensic Medicine: 0 fractional works · 0.4% of its workPhysiology: 0 fractional works · 0.4% of its workComplementary and alternative medicine: 0 fractional works · 0.4% of its workReproductive Medicine: 0 fractional works · 0.3% of its workHealth Professions: 0 fractional works · 1.2% of its workGeneral Health Professions: 0 fractional works · 0.5% of its workComplementary and Manual Therapy: 0 fractional works · 0.2% of its workHealth Information Management: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workNursing: 0 fractional works · 0.2% of its workNutrition and Dietetics: 0 fractional works · 0.2% of its workLife Sciences: 10 fractional works · 27.9% of its workBiochemistry, Genetics and Molecular Biology: 5 fractional works · 13.2% of its workMolecular Biology: 2 fractional works · 7.0% of its workGenetics: 1 fractional works · 1.8% of its workCancer Research: 1 fractional works · 1.8% of its workBiotechnology: 1 fractional works · 1.6% of its workBiochemistry: 0 fractional works · 0.5% of its workCell Biology: 0 fractional works · 0.4% of its workImmunology and Microbiology: 3 fractional works · 7.9% of its workImmunology: 3 fractional works · 7.9% of its workNeuroscience: 1 fractional works · 4.0% of its workCellular and Molecular Neuroscience: 1 fractional works · 2.1% of its workCognitive Neuroscience: 0 fractional works · 1.0% of its workBiological Psychiatry: 0 fractional works · 0.5% of its workNeurology: 0 fractional works · 0.5% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 1.4% of its workPharmaceutical Science: 0 fractional works · 0.9% of its workPharmacology: 0 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.0% of its workAgricultural and Biological Sciences: 0 fractional works · 1.4% of its workEcology, Evolution, Behavior and Systematics: 0 fractional works · 0.9% of its workAnimal Science and Zoology: 0 fractional works · 0.5% of its workSocial Sciences: 3 fractional works · 8.7% of its workPsychology: 2 fractional works · 5.6% of its workClinical Psychology: 1 fractional works · 3.3% of its workSocial Psychology: 1 fractional works · 1.7% of its workDevelopmental and Educational Psychology: 0 fractional works · 0.3% of its workExperimental and Cognitive Psychology: 0 fractional works · 0.3% of its workEconomics, Econometrics and Finance: 1 fractional works · 3.0% of its workFinance: 1 fractional works · 1.9% of its workGeneral Economics, Econometrics and Finance: 0 fractional works · 0.9% of its workSmaller subfields together: 0 fractional works · 0.2% of its workSocial Sciences: 0 fractional works · 0.1% of its workPhysical Sciences: 2 fractional works · 4.5% of its workComputer Science: 1 fractional works · 2.0% of its workComputational Theory and Mathematics: 0 fractional works · 1.0% of its workHuman-Computer Interaction: 0 fractional works · 0.6% of its workInformation Systems: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.0% of its workChemistry: 1 fractional works · 1.4% of its workOrganic Chemistry: 0 fractional works · 1.2% of its workInorganic Chemistry: 0 fractional works · 0.2% of its workEnvironmental Science: 0 fractional works · 0.9% of its workEcology: 0 fractional works · 0.9% of its workMaterials Science: 0 fractional works · 0.2% of its workMaterials Chemistry: 0 fractional works · 0.2% of its workALL ITS WORKEpixPharmaceuticals…36fractional works, 2022-now
Life Sciences28%Physical Sciences5%Health Sciences59%Social Sciences9%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in 2022-now. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 15 fields, with their numbers
    1. Medicine2157.4%
    2. Health Professions01.2%
    3. Nursing00.2%
    1. Biochemistry, Genetics and Molecular Biology513.2%
    2. Immunology and Microbiology37.9%
    3. Neuroscience14.0%
    4. Pharmacology, Toxicology and Pharmaceutics11.4%
    5. Agricultural and Biological Sciences01.4%
    1. Psychology25.6%
    2. Economics, Econometrics and Finance13.0%
    3. Social Sciences00.1%
    1. Computer Science12.0%
    2. Chemistry11.4%
    3. Environmental Science00.9%
    4. Materials Science00.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.29× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 2.47× its world share, 5 worksBiochemistry, Geneti…Immunology and Microbiology: 7.87× its world share, 3 worksImmunology and Micro…Neuroscience: 2.49× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 4.03× its world share, 0 worksPharmacology, Toxico…Chemistry: 0.91× its world share, 0 worksChemistryComputer Science: 0.25× its world share, 1 worksComputer ScienceEnvironmental Science: 0.19× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.07× its world share, 0 worksMaterials ScienceHealth Professions: 0.45× its world share, 0 worksHealth ProfessionsMedicine: 2.99× its world share, 21 worksMedicineNursing: 0.47× its world share, 0 worksNursingEconomics, Econometrics and Finance: 1.39× its world share, 1 worksEconomics, Econometr…Psychology: 1.83× its world share, 2 worksPsychologySocial Sciences: 0.01× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 7.9×. Every wedge is a field page.

All 15 fields, with their numbers
  1. Immunology and Microbiology7.87×3 works
  2. Pharmacology, Toxicology and Pharmaceutics4.03×0 works
  3. Medicine2.99×21 works
  4. Neuroscience2.49×1 works
  5. Biochemistry, Genetics and Molecular Biology2.47×5 works
  6. Psychology1.83×2 works
  7. Economics, Econometrics and Finance1.39×1 works
  8. Chemistry0.91×0 works
  9. Nursing0.47×0 works
  10. Health Professions0.45×0 works
  11. Agricultural and Biological Sciences0.29×0 works
  12. Computer Science0.25×1 works
  13. Environmental Science0.19×0 works
  14. Materials Science0.07×0 works
  15. Social Sciences0.01×0 works

Who are the top researchers at Epix Pharmaceuticals (United States)?

Ranked on the quality score, Edward C. Parsons, Wei‐Chuan Sun and Matthew T. Greenfield lead among researchers whose main affiliation is Epix Pharmaceuticals (United States).

  1. 1 Edward C. Parsons United States · #641,022 worldwide 2.5k citations · 42 works
  2. 2 Wei‐Chuan Sun United States · #1,212,714 worldwide 1.4k citations · 16 works
  3. 3 Matthew T. Greenfield United States · #1,464,661 worldwide 1.9k citations · 36 works
  4. 4 John C. Amedio United States · #1,840,795 worldwide 1.3k citations · 37 works
  5. 5 Audrey L. Shaw United States · #2,182,564 worldwide 3.2k citations · 56 works
All ranked researchers at Epix Pharmaceuticals (United States)

What are the most cited papers from Epix Pharmaceuticals (United States)?

The most cited paper from Epix Pharmaceuticals (United States) is "Strategies for increasing the sensitivity of gadolinium based MRI contrast agents" (Peter D. Caravan, 2006), with 1,430 citations. Next come "Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia" (1,285) and "A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma" (745).

Most cited papers
#PaperReleasedCitations
1 Strategies for increasing the sensitivity of gadolinium based MRI contrast agents Peter D. Caravan · Chemical Society Reviews Review 2006 1,430
2 Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia Marina Cavazzana et al. · Nature Open access Sep 2010 1,285
3 A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology Oct 2004 745
4 Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 Renhai Cao, Ebba Bråkenhielm, Robert Pawliuk et al. · Nature Medicine 31 Mar 2003 728
5 Tracer arrival timing‐insensitive technique for estimating flow in MR perfusion‐weighted imaging using singular value decomposition with a block‐circulant deconvolution matrix Ona Wu, Leif Østergaard, Robert M. Weisskoff et al. · Magnetic Resonance in Medicine 13 Jun 2003 607
All 62 most cited papers, with filters and sorting

Which keywords describe research at Epix Pharmaceuticals (United States)?

By fractional works in 2022-now, weighted toward what it does more of than the world: Inflammation, Immunotherapy, Cancer, Cancer Treatment, Prostate Cancer, Clinical Trials, Genetic Mutations and Targeted Therapy.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in 2022-now in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 28 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 28 words, with their numbers
  1. Inflammation5▲ 6.8×19 topics
  2. Immunotherapy3▲ 12×7 topics
  3. Cancer3▲ 5.6×12 topics
  4. Cancer Treatment2▲ 26×3 topics
  5. Prostate Cancer2▲ 44×2 topics
  6. Clinical Trials2▲ 8.0×4 topics
  7. Genetic Mutations2▲ 12×4 topics
  8. PET Imaging2▲ 28×2 topics
  9. Targeted Therapy2▲ 21×3 topics
  10. Hormone Therapy2▲ 51×2 topics
  11. Radioimmunotherapy2▲ 158×1 topic
  12. Radiopharmaceuticals2▲ 158×1 topic
  13. Androgen Receptor2▲ 57×1 topic
  14. Genomic Profiling2▲ 42×2 topics
  15. Metastatic Prostate Cancer2▲ 102×1 topic
  16. Angiogenesis1▲ 10×3 topics
  17. Enteric Nervous System1▲ 80×2 topics
  18. Gene Therapy1▲ 19×4 topics
  19. Breast Cancer1▲ 13×4 topics
  20. Epidemiology1▼ 0.85×13 topics
  21. Fc Receptors1▲ 59×1 topic
  22. Therapeutic Antibodies1▲ 47×1 topic
  23. Treatment1▲ 2.8×9 topics
  24. Gastrointestinal Disorders1▲ 50×1 topic
  25. Irritable Bowel Syndrome1▲ 86×1 topic
  26. Quality of Life1▲ 2.0×8 topics
  27. Radiotherapy1▲ 7.7×3 topics
  28. Machine Learning1▼ 0.86×3 topics

Which research topics does Epix Pharmaceuticals (United States) publish most on?

By volume in 2022-now: Radiopharmaceutical Chemistry and Applications, Prostate Cancer Treatment and Research, Monoclonal and Polyclonal Antibodies Research and Gastrointestinal motility and disorders.

Radiopharmaceutical Chemistry and Applications: 2 fractional worksProstate Cancer Treatment and Research: 2 fractional worksMonoclonal and Polyclona…1Monoclonal and Polyclonal Antibodies Research: 1 fractional worksGastrointestinal motilit…1Gastrointestinal motility and disorders: 1 fractional worksRNA Interference and Gene Delivery: 1 fractional worksImmune Response and Inflammation: 1 fractional worksChemokine receptors and …1Chemokine receptors and signaling: 1 fractional worksCAR-T cell therapy research: 1 fractional worksProstate Cancer Diagnosis and Treatment: 1 fractional worksImmune cells in cancer1Immune cells in cancer: 1 fractional works
Radiology, Nuclear Medicine and ImagingPulmonary and Respiratory MedicineGastroenterologyMolecular Biology2 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Radiopharmaceutical Chemistry and Applications Radiology, Nuclear Medicine and Imaging 2 works
  2. 2 Prostate Cancer Treatment and Research Pulmonary and Respiratory Medicine 2 works
  3. 3 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
  4. 4 Gastrointestinal motility and disorders Gastroenterology 1 works
  5. 5 RNA Interference and Gene Delivery Molecular Biology 1 works
  6. 6 Immune Response and Inflammation Immunology 1 works
  7. 7 Chemokine receptors and signaling Oncology 1 works
  8. 8 CAR-T cell therapy research Oncology 1 works
  9. 9 Prostate Cancer Diagnosis and Treatment Pulmonary and Respiratory Medicine 1 works
  10. 10 Immune cells in cancer Immunology 1 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available27.1%not open72.9%

World: 40% of research is openly available.

with international co-authors18.1%domestic only81.9%

World: 18% is written across borders.

How has Epix Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 102% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Epix Pharmaceuticals (United States) as a percentage of every work published that year, 0.00015% in 2024.

still counting0.00050%0.0010%Epix Pharmaceuticals (United States)0.00021% in 20251990200020102020

Fractional works of Epix Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Lexington

All research institutions in Lexington

Share Epix Pharmaceuticals (United States)'s ranking

Epix Pharmaceuticals (United States) on Science Explorer

A card with Epix Pharmaceuticals (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Epix Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.